(Reuters) - In previous clinical studies, naproxcinod showed it was more effective than placebo and that it had no detrimental effect on blood pressure when compared with widely used non-steroidal anti-inflammatory drugs .
NicOx aims to file for U.S. marketing approval of naproxcinod in the first quarter of 2009. The efficacy results of the second Phase III trial are expected mid-2008.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment